Department of State **Division of Publications**

312 Rosa L. Parks Ave., 8th Floor, Snodgrass/TN Tower

Nashville, TN 37243 Phone: 615-741-2650

Email: publications.information@tn.gov

For Department of State Use Only

Sequence Number: 03-01-24

Rule ID(s): 10055

File Date: ____

3/1/2024

Effective Date: _____5/30/2024

Rulemaking Hearing Rule(s) Filing Form

Rulemaking Hearing Rules are rules filed after and as a result of a rulemaking hearing (Tenn. Code Ann. § 4-5-205).

Pursuant to Tenn. Code Ann. § 4-5-229, any new fee or fee increase promulgated by state agency rule shall take effect on July 1, following the expiration of the ninety (90) day period as provided in § 4-5-207. This section shall not apply to rules that implement new fees or fee increases that are promulgated as emergency rules pursuant to § 4-5-208(a) and to subsequent rules that make permanent such emergency rules, as amended during the rulemaking process. In addition, this section shall not apply to state agencies that did not, during the preceding two (2) fiscal years, collect fees in an amount sufficient to pay the cost of operating the board, commission or entity in accordance with § 4-29-121(b).

Agency/Board/Commission:	Department of Mental Health and Substance Abuse Services
Division:	Division of Substance Abuse Services
Contact Person:	Krysten Velloff
Address:	500 Deaderick Street, 5th Floor, Andrew Jackson Building, Nashville, TN
Zip:	37243
Phone:	615-881-5280
Email:	Krysten.Velloff@tn.gov

Revision Type (check all that apply):

X	Amendment	Content based on previous emergency rule filed on
	_New	Content is identical to the emergency rule
	Repeal	

Rule(s) (ALL chapters and rules contained in filing must be listed here. If needed, copy and paste additional tables to accommodate multiple chapters. Please make sure that ALL new rule and repealed rule numbers are listed in the chart below. Please enter only ONE Rule Number/Rule Title per row)

Chapter Number	Chapter Title
0940-06-01	Controlled Substances
Rule Number	Rule Title
0940-06-0101	Controlled Substances in Schedule I
0940-06-0102	Controlled Substances in Schedule II
0940-06-0103	Controlled Substances in Schedule III
0940-06-0104	Controlled Substances in Schedule IV
0940-06-0105	Controlled Substances in Schedule V
0940-06-0106	Controlled Substances in Schedule VI
0940-06-0107	Controlled Substances in Schedule VII

0940-06-0108	Non-Narcotic Substances Excluded from Controlled Substances
0940-06-0109	Chemical Preparations Excluded from Controlled Substances
0940-06-0110	Veterinary Anabolic Steroid Implant Products Excluded from Controlled Substances
0940-06-0111	Prescription Products Excluded from Controlled Substances
0940-06-0112	Anabolic Steroid Products Excluded from Controlled Substances
0940-06-0113	Certain Cannabis Plant Material, and Products Made Therefrom, Excluded from Controlled Substances

Place substance of rules and other info here. Please be sure to include a detailed explanation of the changes being made to the listed rule(s). Statutory authority must be given for each rule change. For information on formatting rules go to https://sos.tn.gov/products/division-publications/rulemaking-guidelines.

Chapter 0940-06-01 Controlled Substances Amendments

Rule 0940-06-01-.01 Controlled Substances in Schedule I is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

- (1) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation. For the purposes of subparagraph (hhh)2.(xxiii), 3-Methylfentanyl, only, the term isomer includes the optical and geometric isomers.

(a)	Acetylmethadol	9601
(b)	AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)	9551
(c)	Allylprodine	, 9602
(d)	Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol; levomethadyl acetate; or LAAM)	. 9603
(e)	Alphameprodine	9604
(f)	Alphamethadol	9605
(g)	Benzethidine	. 9606
(h)	Betacetylmethadol	. 9607
(i)	Betameprodine	9608
(j)	Betamethadol	9609
(k)	Betaprodine	. 9611
(1)	Brorphine	. 9098
(m)	Butonitazene	.9751
(n)	Clonitazene	. 9612
(o)	Dextromoramide	. 9613
(p)	Diampromide	. 9615
(p)	Diethylthiambutene	.9616
(r)	Difenoxin	9168
(s)	Dimenoxadol	.9617

(t)	Dimepheptanol	.9618
(u)	Dimethylthiambutene	9619
(v)	Dioxaphetyl butyrate	9621
(w)	Dipipanone	9622
(x)	Ethylmethylthiambutene	9623
(y)	Etodesnitazene	9765
(z)	Etonitazene	9624
(aa)	Etoxeridine	9625
(bb)	Flunitazene	9756
(cc)	Furethidine	9626
(dd)	Hydroxypethidine	9627
(ee)	Isotonitazene	9614
(ff)	Ketobemidone	9628
(gg)	Levomoramide	9629
(hh)	Levophenacylmorphan.	9631
(ii)	Metodesnitazene	9764
(jj)	Metonitazene	9757
(kk)	Morpheridine	9632
(II)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
(mm)	MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)	9560
(nn)	N-pyrrolidino etonitazene	9758
(00)	Noracymethadol	9633
(pp)	Norlevorphanol	9634
(qq)	Normethadone	9635
(rr)	Norpipanone	9636
(ss)	PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine)	9663
(tt)	Phenadoxone	9637
(uu)	Phenampromide	9638
(vv)	Phenomorphan	9647
(ww)	Phenoperidine	9641

(xx)	Piritramide	9642
(yy)	Proheptazine	9643
(zz)	Properidine	9644
(aaa)	Propiram	9649
(bbb)	Protonitazene	9759
(ccc)	Racemoramide	9645
(ddd)	Tillidine	9750
(eee)	Trimeperidine	9646
(fff)	U-47700.	9547
(ggg)	Zipeprol	9873
(hhh)	Fentanyl Derivatives and Analogues	

- - 1. Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a 4-anilidopiperidine structure:
 - (i) With or without substitution at the carbonyl of the aniline moiety with alkyl, alkenyl, carboalkoxy, cycloalkyl, methoxyalkyl, cyanoalkyl, or aryl groups, or furanyl, dihydrofuranyl, benzyl moiety, or rings containing heteroatoms sulfur, oxygen, or nitrogen;
 - (ii) With or without substitution at the piperidine amino moiety with a phenethyl, benzyl, alkylaryl (including heteroaromatics), alkyltetrazolyl ring, or an alkyl or carbomethoxy group, whether or not further substituted in the ring or group;
 - (iii) With or without substitution or addition to the piperdine ring to any extent with one or more methyl, carbomethoxy, methoxy, methoxymethyl, aryl, allyl, or ester groups;
 - With or without substitution of one or more hydrogen atoms for halogens, or methyl, (iv) alkyl, or methoxy groups, in the aromatic ring of the anilide moiety;
 - (v) With or without substitution at the alpha or beta position of the piperidine ring with alkyl, hydroxyl, or methoxy groups;
 - With or without substitution of the benzene ring of the anilide moiety for an aromatic (vi) heterocycle; and
 - (vii) With or without substitution of the piperidine ring for a pyrrolidine ring, perhydroazepine ring, or azepine ring;
 - 2. Excluding, Alfentanil, Carfentanil, Fentanyl, and Sufentanil; including, but not limited to:
 - (i) Acetylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)......9821
 - Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidnyl]-N-(ii)

(iii)	Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) 9811
(iv)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1- methyl-2-phenylethyl)-4-(N-
	propanilido)piperidine)
(v)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
(vi)	Benzodioxolefentanyl
(vii)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)9830
(viii)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N- phenylpropionamide; N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N- phenylpropanamide)
(ix)	Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N- phenylpropanamide)
(x)	Beta-Methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide
(xi)	Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) 9842
(xii)	Butyrylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide)9822
(xiii)	Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N- phenylbut-2-enamide)
(xiv)	Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide)
(xv)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide)
(xvi)	Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate)
(xvii)	2'-Fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-n-(2-fluorophenyl)propionamide)
(xviii)	Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)9834
(xix)	Isobutyryl fentanyl (N-(1-phenethylpiperidin-4yl)-N-phenylisobutyramide) 9827
(xx)	Lofentanil
(xxi)	Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)
(xxii)	4'-Methyl acetyl fentanyl (N-(1-(4- methylphenethyl)piperidin-4-yl)-N-phenylacetamide9819

(xxiii)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)
(xxiv)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
(xxv)	Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide) 9838
(xxvi)	Ohmefentanyl
(xxvii)	Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide)9852
(xxviii)	Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
(xxix)	Ortho-fluorofentanyl (2-fluorofentanyl;N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- yl)propionamide)
(xxx)	Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin -4- yl)isobutyramide)
(xxxi)	Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide)
(xxxii)	Ortho-Methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4- yl)acetamide
(xxxiii)	Para-chloroisobutyryl fentanyl (N-(4-chloropenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide)
(xxxiv)	Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)9823
(xxxv)	Para-fluorofentanyl. (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide)
(xxxvi)	Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2- carboxamide)
(xxxvii)	Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide; 4- fluoroisobutyryl fentanyl 9824
(xxxviii)	Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
(xxxix)	Para-methylfentanyl (N-(4-methylphenyl)-N-(1- phenethylpiperidin-4-yl)propionamide)
(xl)	Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide)9841
(xli)	Pentanoyl fentanyl
(xlii)	Tetrahydrofuranyl fentanyl (N-(1- phenethylpiperidin-4-yl)- nphenyltetrahydrofuran-2- carboxamide)9843
(xliii)	Thiofentanyl

(xliv)	Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylthiophene-2-carboxamide
(xlv)	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)

(3) Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(a)	Acetorphine
(b)	Acetyldihydrocodeine
(c)	Benzylmorphine
(d)	Codeine methylbromide
(e)	Codeine-N-Oxide
(f)	Cyprenorphine
(g)	Desomorphine
(h)	Dihydromorphine
(i)	Drotebanol 933
(j)	Etorphine (except hydrochloride salt)
(k)	Heroin
(1)	Hydromorphinol
(m)	Methyldesorphine
(n)	Methyldihydromorphine
(o)	Morphine methylbromide
(p)	Morphine methylsulfonate 9306
(p)	Morphine-N-Oxide
(r)	Myrophine
(s)	Nicocodeine
(t)	Nicomorphine 9312
(u)	Normorphine
(v)	Pholcodine 9314
(w)	Thebacon

⁽⁴⁾ Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and

salts of isomers, is possible within the specified chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

(a)	Alpha-ethyltryptamine	'249
(b)	Alpha-methyltryptamine	'432
(c)	Alpha-pyrrolidinobutiophenone	′546
(d)	Alpha-pyrrolidinopentiophenone	545
(e)	4-Bromo-2,5-dimethoxyamphetamine	
(f)	4-Bromo-2,5-dimethoxyphenethylamine	
(g)	2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	536
(h)	Bufotenine	433 -5-
(i)	Butylone	541
(j)	2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	537
(k)	Diethyltryptamine	434
(1)	2,5-Dimethoxyamphetamine	396
(m)	2,5-Dimethoxy-4-ethylamphetamine	399
(n)	2,5 2,5 Dimethoxy-4propylthiophenethylamine	348
(0)	Dimethyltryptamine	435
(p)	Ethylamine analogue of phencyclidine	455
(q)	2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one	286

(r)	Ethylone
(s)	Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 7036 Other name: 5F- EDMB-PINACA
(t)	(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone
(u)	3-Fluoro-N-methylcathinone
(v)	4-Fluoro-N-methylcathinone
(w)	1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
(x)	Ibogaine
(y)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(z)	Lysergic acid diethylamide
(aa)	Mescaline
(bb)	4-Methoxyamphetamine
(cc)	5-Methoxy-3,4-methylenedioxyamphetamine
(dd)	5-Methoxy-N,N-diisopropyltryptamine
(ee)	5-methoxy-N,N-dimethyltryptamine
(ff)	4-Methyl-N-ethylcathinone. 1249 Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one
(gg)	4-Methyl-alpha-pyrrolidinopropiophenone
(hh)	Methyl 2-(1-(cyclohexylmethyl)-1h-indole-3-carboxamido)-3,3-dimethylbutanoate 7042 Other names: MDMB-CHMICA, MMB-CHMINACA
(ii)	4-Methyl-2,5-dimethoxyamphetamine
(jj) 39 (Nov	3,4-Methylenedioxyamphetamine

(kk)	3,4-Methylenedioxymethamphetamine
(II)	3,4-Methylenedioxy-N-ethylamphetamine
(mm)	3,4-Methylenedioxy-N-methylcathinone
(nn)	Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate7020 Other names: MDMB-FUBINACA
(00)	Methyl 2- (1-(4-fluorobutyl)-1h-indazole-3-carboxamido)-3,3-dimethylbutanoate7043 Other name: 4F-MDMB-BINACA
(pp)	Methyl2-(1-(5-fluoropentyl)-1h-indazole-3-carboxamido)-3,3-dimethylbutanoate7034 Other names: 5F-ADB; 5F-MDMB-PINACA
(qq)	Methyl 2-(1-(5-fluoropentyl)-1h-indazole-3-carboxamido)-3- methylbutanoate
(rr)	Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate7041 Other name: 5F-MDMB-PICA
(ss)	N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide7047 Other names: FUB-AKB48, FUB-APINACA, AKB48 N-(4-FLUOROBENZYL)
(tt)	N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
(uu)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)1H-indazole-3-carboxamide 7010 Other name: ADB-FUBINACA
(vv)	Naphyrone
(ww)	Naphthalen-1-yl 1-(5-fluoropentyl)-1 h-indole-3-carboxylate
(xx)	N-Ethyl-3-piperidyl benzilate7482
(yy)	N-Hydroxy-3,4-methylenedioxyamphetamine
(ZZ)	N-methyl-3-piperidyl benzilate
(aaa)	Parahexyl
(bbb)	Para-methoxymethamphetamine
(ccc)	Pentedrone

11

RDA 1693

SS-7039 (November 2022)

	Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one
(ddd)	Pentylone
(eee)	Peyote
(fff)	Psilocybin (constituent of magic mushrooms)
(ggg)	Psilocyn (constituent of magic mushrooms)
(hhh)	Pyrrolidine analogue of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine)7458 Other names: PCPy; PHP
(iii)	1-[1-(2-Thienyl)cyclohexyl]pyrrolidine
(jjj)	4-Methylmethcathinone
(kkk)	3,4-Methylenedioxypyrovalerone
(III)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)
(mmm)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7508
(nnn)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
(000)	2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-l)
(ppp)	2-[4-Ethylthio-2,5-dimethoxyphenyl]ethanamine (2C-T-2)7385
(ppp)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
(rrr)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
(sss)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)
(ttt)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
(uuu)	Thiophene analogue of phencyclidine
(vvv)	3,4,5-Trimethoxyamphetamine
(www)	(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
(xxx)	1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone

	(yyy)	(1-(5-Fluoropentyl)-1H-indazol-3-yl)(naphthale Other name: THJ-2201	n-1-yl)methanone	7024
	(ZZZ)	5F-CUMYL-P7AICAOther names: 1-(5-fluoropentyl)-n-(2-phenylpr carboxamide		7085
	(aaaa)	MMB-CHMICAOther names: methyl-2-(1-(cyclohexylmethyl)-AMB-CHMICA		
	(bbbb)	4-CN-CUMYL-BUTINACAOther names: 1-(4-cyanobutyl)-N-(2-phenylprocyano-CUMYL-BUTINACA; 4-CN-CUMYL Bl	opan-2-yl)-1H-indazole-3-carboxamide; 4	
	(cccc)	5F-AB-PINACAOther names: N-(1-amino-3-methyl-1-oxobuta carboxamide		7025
	(dddd)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cycle carboxamide Other name: AB-CHMINACA		7031
	(eeee)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flucarboxamide Other name: AB-FUBINACA		7012
	(ffff)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carbo Other names: APINACA; AKB48	xamide	7048
	(9999)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pe Other name: ADB-PINACA	entyl-1H-indazole-3-carboxamide	7035
	(hhhh)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-penty Other name: AB-PINACA	I-1H-indazole-3-carboxamide	7023
	(iiii)	Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-ca Other names: 5-fluoro-PB-22; 5F-PB-22	arboxylate	7225
	(زززز)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate Other names: PB-22; QUPIC		7222
	(kkkk)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cits optical, positional, and geometric isomers, so Other names: MAB-CHMINACA; ADB-CHMIN	salts and salts of isomers	
	(IIII)	Methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-cart Other names: FUB-AMB, MMB-FUBINACA, A		7021
(5)	or prepared	sants. Unless specifically excepted or unless list aration which contains any quantity of the follows system, including its salts, isomers, and salts as of isomers is possible within the specified ch	wing substances having a depressant eff of isomers whenever the existence of su	ect on the central
	(a)	EtizolamOther names; Etilaam, Etizola, Sedekopan, Pa		2780
	(b)	Gamma-hydroxybutyric acid		2010
SS-7	039 (Nov	ember 2022) 13	3	RDA 1693

Other names: GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate

	(c)	Mecloqualone	2572
	(d)	Methaqualone	2565
(6)	prepa	lants. Unless specifically excepted or unless listed in another schedule, any material, contration which contains any quantity of the following substances having a stimulant effect ous system, including its salts, isomers, and salts of isomers: Amineptine Other names: 7-[(10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid	on the central
	(b)	Alpha-Pyrrolidinoheptaphenone	7548
	(c)	Alpha-Pyrrolidinohexanophenone Other names: α-PHP, alpha-pyrrolidinohexiophenone, 1-phenyl-2-(pyrrolidin-1-yl)hexarone	
	(d)	Aminorex Other names: aminoxophen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine	1585
	(e)	Cathinone Other names: 2- amino-1-phenyl-1-propanone; alpha-aminopropiophenone; 2-aminopropiophenone; norphedrone; constituent of catha edulis or "Khat" plant	
	(f)	4'-Chloro-alpha-pyrrolidinovalerophenone Other names: 4-chloro-α-PVP, 4'-chloro-alpha-pyrrolidinopentiophenone, 1-(4-chlorophenophenone) 2-(pyrrolidin-1-yl)pentan-1- one	
	(g)	4,4'-Dimethylaminorex Other names: 4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine	1595
	(h)	EphyloneOther names: N-ethylpentylone; 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one	7543
	(i)	Fenethylline	1503
	(j)	MesocarbOther names: N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl) carbamimidate	1227
	(k)	Methcathinone Other names: 2-(methylamino)-propiophenone; alpha-(methylamino) propiophenone; 2 (methylamino)-1-phenylpropan-1- one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-42 463; and UR1432	-
	(I)	MethiopropamineOther names: N-methyl-1-(thiophen-2-yl)propan-2- amine	1478
	(m)	4-Methyl-alpha-ethylaminopentiophenone Other names: 4-MEAP, 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one	7245
	(n)	4'-Methyl-alpha-pyrrolidinohexiophenoneOther names: MPHP, 4'-methyl-alpha-pyrrolidinohexanophenone,1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one	7446

	(o)	(+/-) cis-4-Methylaminorex (cis isomer)
	(p)	N-Benzylpiperazine
	(q)	N-Ethylamphetamine
	(r)	N-Ethylhexedrone
	(s)	N,N-Dimethylamphetamine
(7)	compo their sa	bimimetic agents. Unless specifically exempted or unless listed in another schedule, any material, und, mixture, or preparation which contains any quantity of the following substances, or which contains alts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is e within the specific chemical designation:
	(a)	5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)7297
	(b)	5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8- homolog)
	(c)	1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)
	(d)	1-Butyl-3-(1-naphthoyl)indole (JWH-073)
	(e)	1-Hexyl-3-(1-naphthoyl)indole (JWH-019)
	(f)	1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)
	(g)	1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)
	(h)	1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)7081
	(i)	1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)
	(j)	1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)
	(k)	1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)
	(I)	1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)7694
	(m)	1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4)
	(n)	1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)7008
	(0)	1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)
Authori	ty: T.C.A	A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.02 Controlled Substances in Schedule II is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

- (1) Schedule II consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
 - (a) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, thebaine-derived butorphanol, naldemedine, nalmefene, nalbuphine, naloxegol, naloxone, 6β-naltrexol and naltrexone, and their respective salts, but including the following:

1.	Codeine 9050
2.	Dihydroetorphine
3.	Ethylmorphine9190
4.	Etorphine hydrochloride
5.	Granulated opium
6.	Hydrocodone
7.	Hydromorphone9150
8.	Metopon9260
9.	Morphine
10.	Noroxymorphone
11.	Opium extracts
12.	Opium fluid9620
13.	Oripavine9330
14.	Oxycodone
15.	Oxymorphone 9652
16.	Powdered opium
17.	Raw opium
18.	Thebaine
19.	Tincture of opium

- (b) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (2)(a) of this rule, except that these substances shall not include the isoquinoline alkaloids of opium.
- (c) Opium poppy and poppy straw
- (d) Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves

(including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.

- (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy).......9670
- Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

(a)	Alfentanil97	737
(b)	Alphaprodine90	010
(c)	Anileridine90)20
(d)	Bezitramide	300
(e)	Carfentanil97	743
(f)	Dextropropoxyphene (bulk, non dosage forms)	273
(g)	Dihydrocodeine 91	120
(h)	Diphenoxylate91	170
(i)	Fentanyl98	301
(j)	Isomethadone92	226
(k)	Levo-alphacetylmethadol96 Other names: levo-alpha-acetylmethadol; levomethadyl acetate; LAAM	348
(I)	Levomethorphan 92	210
(m)	Levorphanol92	220
(n)	Metazocine 92	240
(o)	Methadone	250
(p)	Methadone-Intermediate; 4-cyano-2-dimethylamino-4,4-diphenyl butane92	254
(p)	Moramide-Intermediate; 2-methyl-3-morpholino-1,1-diphenylpropane-caboxylic acid98	302
(r)	Oliceridine92	245
(s)	Pethidine (meperidine)92	230
(t)	Pethidine-Intermediate-A; 4-cyano-1-methyl-4-phenylpiperidine	232
(u)	Pethidine-Intermediate-B; ethyl-4-phenylpiperidine-4-carboxylate92	233
(v)	Pethidine-Intermediate-C; 1-methyl-4-phenylpiperidine-4-carboxylic acid92	234

	(w)	Phenazocine971	5
	(x)	Piminodine973	0
	(y)	Racemethorphan973	2
	(z)	Racemorphan973	3
	(aa)	Remifentanil	9
	(bb)	Sufentanil	0
	(cc)	Tapentadol9780)
	(dd)	Thiafentanil9729	9
(4)	prepar	lants. Unless specifically excepted or unless listed in another schedule, any material, compound ration which contains any quantity of the following substances having a stimulant effect on the cus system:	
	(a)	Amphetamine, its salts, optical isomers, and salts of its optical isomers1100	0
	(b)	Methamphetamine, its salts, isomers, and salts of its isomers	5
	(c)	Phenmetrazine and its salts	1
	(d)	Methylphenidate	4
	(e)	Lisdexamfetamine, its salts, isomers, and salts of its isomers	5
(5)	or prep nervou	ssants. Unless specifically excepted or unless listed in another schedule any material, compour paration which contains any quantity of the following substances having a depressant effect on us system, including its salts, isomers, and salts of isomers whenever the existence of such sal alts of isomers is possible within the specific chemical designation:	the central
	(a)	Amobarbital 2125	5
	(b)	Glutethimide)
	(c)	Pentobarbital 2270)
	(d)	Phencyclidine7471	I
	(e)	Secobarbital	5
(6)	Hallucii	inogenic substances.	
	(a)	Nabilone)
	(b)	Dronabinol in oral solution in drug product approved for marketing by United States Food and Drug Administration	;
(7)	Immedi	liate precursors. Unless specifically excepted or unless listed in another schedule, any material	. compound.

- (a) Immediate precursor to amphetamine and methamphetamine:
 - Phenylacetone.......8501
 Other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone
- (b) Immediate precursors to phencyclidine (PCP):
- (c) Immediate precursor to fentanyl:
- (8) Tianeptine and any salt, sulfate, free acid, or other preparation of tianeptine, and any salt, sulfate, free acid, compound, derivative, precursor, or other preparation thereof that is substantially chemically equivalent or identical with tianeptine.

Rule 0940-06-01-.03 Controlled Substances in Schedule III is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

- (1) Schedule III consists of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

 - (d) Clortermine. 1647
- (3) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect in the central nervous system:

19

(a) Any compound, mixture, or preparation containing:

	1.	Amobarbital	2126
	2.	Secobarbital	2316
	3.	PentobarbitalOr any salt thereof and one or more other active medicinal ingredients which listed in any schedule.	2271 ch are not
(b)	Any s	suppository dosage form containing:	
	1.	Amobarbital	2126
	2.	Secobarbital	2316
	3.	PentobarbitalOr any salt of these drugs and approved by the Food and Drug Administra marketing only as a suppository.	
(c)		substance which contains any quantity of a derivative of barbituric acid or any supplies include the following drugs	
	1.	Aprobarbital	2100
	2.	Butabarbital (secbutabarbital)	2100
	3.	Butalbital	2100
	4.	Butobarbital (butethal)	2100
	5.	Talbutal	2100
	6.	Thiamylal	2100
	7.	Thiopental	2100
	8.	Vinbarbital	2100
(d)	Chlor	hexadol	2510
(e)	Embu	utramide	2020
(f)	Gamma hydroxybutyric acid preparations. Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under § 505 of the federal Food, Drug, and Cosmetic Act, codified in 21 U.S.C. §§ 301, et seq2012		
(g)	Ketar Other	mine, its salts, isomers, and salts of isomersr name: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone	7285
(h)	Lyser	gic acid	7300
(i)	Lyser	rgic acid amide	7310
(j)	Methy	yprylon	2575
(k)	Peran	mpanel, and its salts, isomers, and salts of isomers	2261
(I)	Sulfor	ndiethylmethane	2600

	(m)	Sulfon	ethylmethane	2605
	(n)	Sulfon	methane	2610
	(o)	Tiletar	nine and zolazepam or any salt of tiletamine or zolazepam	7295
		1.	Other name for a tiletamine-zolazepam combination product: Telazol®.	
		2.	Other name for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.	
		3.	Other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolee],[1,4]- diazepin-7(1H)-one; flupyrazapon.	o[3,4-
(4)	Nalorp	hine		9400
(5)	Narcot	tic Drugs		
	(a)	prepar	s specifically excepted or unless listed in another schedule, any material, compoun ation containing any of the following narcotic drugs, or their salts calculated as the or alkaloid, in limited quantities as set forth below:	
		1.	Not more than 8 grams of codeine per 100 milliliters or not more than 90 milligrar dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium	1
		2.	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligr dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts	-
		3.	Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amounts	
		4.	Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amounts	
		5.	Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredirecognized therapeutic amounts	ents in
		6.	Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with or more active, non-narcotic ingredients in recognized therapeutic amounts	
	(b)	Any ma salts:	aterial, compound, mixture, or preparation containing any of the following narcotic o	Irugs or their
		1.	Buprenorphine	.9064
(6)			ds. Unless specifically excepted or unless listed in another schedule, any material paration containing any quantity of the following substances, including its salts, este	
	(a)	Anabol	lic steroids	4000
		1.	3[alpha],17[beta]-dihydroxy-5a-androstane	
		2.	17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane	

- 3. 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5a-androstane
- 4. 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene
- 5. 17[alpha]-methyl-[delta]1-dihydrotestosterone(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]- androst-1-en-3-one) Other name: 17-[alpha]-methyl-1-testosterone
- 6. 17[alpha]-methyl-4-hydroxynandrolone(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3- one)
- 7. 1-Androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
- 8. 1-Androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
- 9. 4-Androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene)
- 10. 5-Androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene)
- 11. 1-Androstenedione (5[alpha]-androst-1-en-3,17-dione)
- 12. 4-Androstenedione (androst-4-en-3,17-dione)
- 13. 5-Androstenedione (androst-5-en-3,17-dione)
- 14. 3[Beta],17[Beta]-dihydroxy-5a-androstane
- 15. 13[Beta]-ethyl-17[beta]-hydroxygon-4-en-3-one
- 16. Androstanedione (5[alpha]-androstan-3,17-dione)
- 17. Bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- 18. Boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one)
- 19. Boldione (androsta-1,4-diene-3,17-dione)
- 20. Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one) Other name: 4-Chlorotestosterone
- 22. Dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3- one)
- 23. [Delta]1-dihydrotestosterone (a.k.a.'1-testosterone') (17[Beta]-hydroxy-5[alpha]-androst-1-en-3- one)
- 24. Desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[Beta]-ol) Other name: madol
- 25. 4-Dihydrotestosterone (17[beta]-hydroxyandrostan-3-one)
- 26. Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one)
- 27. Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene)
- 28. Fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one)

- 29. Formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one)
- 30. Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)
- 31. 4-Hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one)
- 32. 4-Hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one)
- 33. Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 34. Mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 35. Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-diene-3-one)
- 36. Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene)
- 37. Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one)
- 38. Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 39. Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one)
- 40. Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one)
- 41. Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4, 9,11-trien-3-one)
- 42. Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one)
- 43. Nandrolone (17[beta]-hydroxyestr-4-en-3-one)
- 44. 19-Nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
- 45. 19-Nor-4-androstenediol (3[alpha],17[beta]-dihydroxyestr-4-ene)
- 46. 19-Nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene)
- 47. 19-Nor-5-androstenediol (3[alpha],17[beta]-dihydroxyestr-5-ene)
- 48. 19-Nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene)
- 49. 19-Nor-4-androstenedione (estr-4-en-3,17-dione)
- 50. 19-Nor-5-androstenedione (estr-5-en-3,17-dione)
- 51. Norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one)
- 52. Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one)
- 53. Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one)
- 54. Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one)
- 55. Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one)
- 56. Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one)

- 57. Oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-[5[alpha]]-androstan-3- one)
- 58. Prostanozol (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pryazole)
- 59. Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]-androst-2-eno[3,2-c]-pyrazole)
- 60. Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one)
- 61. Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1, 4-dien-17-oic acid lactone)
- 62. Testosterone (17[beta]-hydroxyandrost-4-en-3-one)
- 63. Tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4, 9,11-trien-3-one)
- 64. Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one)
- (b) Any salt, ester, or isomer of a drug or substance described or listed in subparagraph (a), if such salt, ester, or isomer promotes muscle growth.
- (c) Anabolic steroids intended for administration to cattle or other non-human species are exempt from this rule unless such steroids are prescribed, dispensed, or distributed for human use.
- (d) Anabolic steroids with a combination of estrogens intended for administration to hormone deficient women are exempt from this rule unless such steroids are prescribed, dispensed, or distributed to women who are not hormone deficient.
- (7) Hallucinogenic Substances

Rule 0940-06-01-.04 Controlled Substances in Schedule IV is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

- (1) Schedule IV consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
- (3) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, SS-7039 (November 2022)
 24
 RDA 1693

or preparation which contains any quantity of the following substance, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(a)	Alfaxalone	2731
(b)	Alprazolam	2882
(c)	Barbital	2145
(d)	Brexanolone	2400
(e)	Bromazepam	2748
(f)	Camazepam	2749
(g)	CarisoprodolOther name: Soma®	8192
(h)	Chloral betaine	2460
(i)	Chloral hydrate	2465
(j)	Chlordiazepoxide	2744
(k)	Clobazam	2751
(I)	Clonazepam	2737
(m)	Clorazepate	2768
(n)	Clotiazepam	2752
(0)	Cloxazolam	2753
(p)	Daridorexant	2410
(q)	Delorazepam	2754
(r)	Diazepam	2765
(s)	Dichloralphenazone	2467
(t)	Estazolam	2756
(u)	Eszopiclone	N/A
(v)	Ethchlorvynol	2540
(w)	Ethinamate	2545
(x)	Ethyl Loflazepate	2758
(y)	Fludiazepam	2759
(7)	Fluritrazenam	2763

(aa)	Flurazepam	2767
(bb)	Fospropofol	2138
(cc)	Halazepam	2762
(dd)	Haloxazolam	2771
(ee)	Ketazolam	2772
(ff)	Lemborexant	2245
(gg)	Loprazolam	2773
(hh)	Lorazepam	2885
(ii)	Lormetazepam	2774
(jj)	Mebutamate	2800
(kk)	Medazepam	2836
(II)	Meprobamate	2820
(mm)	Methohexital	2264
(nn)	Methylphenobarbital (mephobarbital)	2250
(00)	Midazolam	2884
(pp)	Nimetazepam	2837
(qq)	Nitrazepam	2834
(rr)	Nordiazepam	2838
(ss)	Oxazepam	2835
(tt)	Oxazolam	2839
(uu)	Paraldehyde	2585
(vv)	Petrichloral	2591
(ww)	Phenobarbital	2285
(xx)	Pinazepam	2883
(yy)	Prazepam	2764
(zz)	Quazepam	2881
(aaa)	Remimazolam	2846
(bbb)	Suvorexant	2223
(ccc)	Temazepam	2925

	(ddd)	Tetrazepam	2886
	(eee)	Triazolam	2887
	(fff)	Zaleplon	2781
	(ggg)	Zolpidem	2783
	(hhh)	Zopiclone	2784
(4)	substa	serin. Any material, compound, mixture, or preparation which contains any quantity of the founces, including its salts, isomers, and salts of such isomers, whenever the existence of such isomers is possible:	
	(a)	Lorcaserin	1625
(5)	prepar	ants. Unless specifically excepted or unless listed in another schedule, any material, composition which contains any quantity of the following substances having a stimulant effect on us system, including its salts, isomers and salts of isomers:	
	(a)	Cathine ((+)-norpseudoephedrine)	1230
	(b)	Diethylpropion	1610
	(c)	Fencamfamin	1760
	(d)	Fenproporex	1575
	(e)	Mazindol	1605
	(f)	Mefenorex	1580
	(g)	Modafinil	1680
	(h)	Pemoline (including organometallic complexes and chelates thereof)	1530
	(i)	Phentermine	1640
	(j)	Pipradol	1750
	(k)	Serdexmethylphenidate	1729
	(1)	Sibutramine	1675
	(m)	Solriamfetol	1650
	(n)	SPA ((-)-1-dimethylamino-1,2-diphenylethane)	1635
(7)		substances. Unless specifically excepted or unless listed in another schedule, any material, e, or preparation which contains any quantity of the following substances, including its salts	
	(a)	Pentazocine	. 9709
	(b)	Butorphanol (including its optical isomers)	. 9720
	(c)	Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-

phenyl- 1H-imidazol-2-yl)ethyl]am	nino]methyl]-2-methoxybenzoic a	cid) (including its optical
somers) and its salts, isomers, an	nd salts of isomers	9725

Rule 0940-06-01-.05 Controlled Substances in Schedule V is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

- (1) Schedule V consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
 - (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
 - (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
 - (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
 - (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
 - (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
 - (f) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
- (3) Stimulants. Unless specifically exempted or excluded, or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers:
- (4) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
 - (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4- propylpyrrolidin-1-yl] butanamide).......2710

 - (c) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester].........2779
 - (d) Gabapentin [1-(aminomethyl)cyclohexaneacetic acid]
 - (e) Ganaxolone (3-alpha-hydroxy-3-beta-methyl-5-alpha-pregnan-20-one)......2401

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.06 Controlled Substances in Schedule VI is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

- (3) Unless specifically excepted or unless listed in another schedule, synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity. Examples include the following drugs or their compounds regardless of numerical designation of atomic positions covered:
 - (a) 1 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (b) 6 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (c) 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.07 Controlled Substances in Schedule VII is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Butyl nitrite and any isomer of butyl nitrite.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.08 Non-Narcotic Substances Excluded from Controlled Substances is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Non-narcotic substances listed in the most current edition of 21 C.F.R. 1308.22, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.09 Chemical Preparations Excluded from Controlled Substances is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Chemical preparations listed in the most current edition of 21 C.F.R. 1308.24, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.10 Veterinary Anabolic Steroid Implant Products Excluded from Controlled Substances is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Veterinary anabolic steroid implant products listed in the most current edition of 21 C.F.R. 1308.26, are excluded from all schedules.

Rule 0940-06-01-.11 Prescription Products Excluded from Controlled Substances is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Prescription products listed in the most current edition of 21 C.F.R. 1308.32, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.12 Anabolic Steroid Products Excluded from Controlled Substances is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Anabolic steroid products listed in the most current edition of 21 C.F.R. 1308.34, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Rule 0940-06-01-.13 Certain Cannabis Plant Material, and Products Made Therefrom, Excluded from Controlled Substances is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read:

(1) Certain cannabis plant material, and products made therefrom, that contain tetrahydrocannabinols listed in the most current edition of 21 C.F.R. 1308.35, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

* If a roll-call vote was necessary, the vote by the Agency on these rulemaking hearing rules was as follows:

Board Member	Aye	No	Abstain	Absent	Signature (if required)
			li di		

	h and Substance Abu	se Services (board	es, lawfully promulgated and adopted by the d/commission/ other authority) on 12/07/2023,
I further certify the following:			
Notice of Rulemaking Hearing filed wi	th the Department of	State on:	06/30/2023
Rulemaking Hearing(s) Conducted on:	: (add more dates).	08/28/2023	
	Date:	12/07/2023	
	Signature:	Mari Val	lus
	Name of Officer:	Marie Williams, I	LCSW
	Title of Officer:	Commissioner, and Substance A	Tennessee Department of Mental Health buse Services
	Date:	12/28/2023	
	Signature:_	Poslain	
	Name of Officer:	Ralph Alvarado	, MD, FACP
	Title of Officer:	Commissioner,	Tennessee Department of Health
Agency/Board/Commission: Tennes Rule Chapter Number(s): 0940-06-01		ental Health and S	Substance Abuse Services
All rulemaking hearing rules provided for herein have been examined by the Attorney General and Reporter of the State of Tennessee and are approved as to legality pursuant to the provisions of the Administrative Procedures Act, Tennessee Code Annotated, Title 4, Chapter 5.			
	£I		Jonathan Skrmetti
		/	Attorney General and Reporter
		-	Es. 27, 7004 Date
Department of State Use Only			
RECEIVED	Filed with the Depar	tment of State on:	3/1/2024
		Effective on:	5/30/2024
Mar 01 2024, 3:55 pm Secretary of State Division of Publications			Le langett
DIVISION OF LADIICATIONS			7 Tre Hargett

Tre Hargett Secretary of State

Public Hearing Comments
One copy of a document that satisfies T.C.A. \S 4-5-222 must accompany the filing.
Please see attached memo.

TDMHSAS Responses to Comments about Rules Chapter 0940-06-01 Controlled Substances

made prior to, during, or after the Rulemaking Hearing held on August 28, 2023

*The Department has attempted to present the following comments in a form that is both easy to ready and accurate to the intent of the commenter. In rare cases, the Department made technical edits to increase the readability of a comment. Please forgive any typographical errors in both the comments and responses.

**All citations referenced by the stakeholders in this section refer to the version of the rule as it appeared in the Notice of Rulemaking Hearing document filed by TDMHAS with the Secretary of State on June 30, 2023.

GENERAL COMMENTS

DAVID B. RAUSCH, DIRECTOR, TENNESSEE BUREAU OF INVESTIGATION:

The TBI and the TBI's Dangerous Drugs Task Force supports the Tennessee Department of Mental Health and Substance Abuse Services (MHSAS) in addressing the escalating issues related to the use of fentanyl and xylazine. Xylazine emulates certain opioid effects, substantially increasing the risk of fatal overdose and hindering established life-saving interventions, especially when fentanyl is added. A decade ago, the Bureau's Forensic Services Division had never had an evidence submission for Xylazine. Even three years ago, xylazine was identified in less than ten cases. Unfortunately, the prevalence of Xylazine is skyrocketing. Last year it was identified in 192 submissions to the TBI labs. This year has already surpassed that total and is on pace for over 500 cases. This emerging trend not only poses a serious threat to individual health but also inflicts profound pain on the afflicted families. We believe properly scheduling Xylazine will help to mitigate the significant public health and safety risks associated with this illicit combination and will make our communities safer.

TDMHSAS Response:

The Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) thanks TBI for their comments., TDMHSAS will continue to work with the Tennessee Bureau Of Investigation, as well other public and private stakeholders, to gather additional data, provide education, and monitor related changes at the federal level and will consider scheduling xylazine in future rule promulgation.

SPECIFIC COMMENTS

Chapter 0940-06-01-.03 Controlled Substances in Schedule III

FORREST REYNOLDS, DVM, PRESIDENT, TENNESSEE VETERINARY MEDICAL ASSOCIATION (TVMA):

The Tennessee Veterinary Medical Association respectfully requests the department to reconsider the scheduling of the veterinary drug xylazine at this time. It is vital to the safe practice of veterinary medicine in Tennessee.

Xylazine is a non-narcotic veterinary sedative, analgesic, and muscle relaxant that has been approved in the United States for veterinary use since 1972. It is used throughout veterinary medicine and is especially important when working with cattle, horses, zoo, wildlife, and laboratory species to facilitate safe medical evaluation, treatment, and surgical care. Specifically, there is no other practical alternative for sedation in cattle.

According to the Tennessee Department of Agriculture, beef cattle are consistently among the top three for Tennessee's agricultural commodities, accounting for 16.7% of all agriculture cash receipts. The state is home to more then 45,000 operations and 2 million cattle. Due to the large stature of these animals, many veterinary care procedures require the use of xylazine to ensure the safety of the owners, animals and veterinary professionals. These surgical procedures would not be possible or would be inhumane without such a short-term sedative/analgesic.

In addition, the effects of xylazine can be reversed using an antidote administered by a veterinarian. Thereby hastening the recovery of the animal. This is specifically useful in cattle and horses because it helps avoid bloat if they are down for too long. Failure to recover either species as rapidly as possible often results in the death of the patient.

Veterinarians in Tennessee fear the loss of availability of xylazine without which they would not be able to properly treat certain patients. There are currently only two manufacturers of xylazine for veterinary use in the United States. Xylazine is a low-volume generic drug that generates little revenue for manufacturers, and we do not believe there is a significant diversion from the legitimate veterinary distribution channel. Increased regulations on legitimate xylazine to address illicit xylazine will result in supply chain disruptions or eliminate the product from the market. If xylazine is scheduled as a controlled substance without an exception for veterinary use, there is a very real risk that it will cease to be available in Tennessee because of the increased regulatory burden and costs for the manufacturers and distributors.

Xylazine is prescribed and dispensed in very rare cases outside of a veterinary clinic since its use is intended for sedation during procedures performed by a veterinarian. Thus, information about it is not expected to be captured by the Tennessee Controlled Substance Monitoring Database.

Veterinarians understand the desire to combat illicit xylazine due to its increased usage in street drugs. We support the American Veterinary Medical Association's diligent work at the federal level to help craft laws and regulations that will make a difference and maintain its availability to our profession.

During the 2023 legislative session, TVMA worked closely with the bill sponsors of HB1242/SB1398 regarding xylazine. This new law criminalizes possessing, manufacturing, delivering, or selling xylazine in Tennessee while exempting legitimate veterinary practice and possession by non-veterinarians with valid prescriptions from a licensed veterinarian. This was an attempt to ensure law enforcement can arrest those in possession of xylazine, while not endangering its availability to veterinarians. In keeping with this recently enacted law, we respectfully request that any rule related to scheduling of xylazine exempt use in legitimate veterinary practice.

The TVMA applauds the department for its work to provide mental health, drug and addiction services to those in our state who need it most. We understand the desire to curb the use of xylazine mixed with other dangerous drugs but hope we have provided sufficient information about its necessity in the practice of veterinary medicine. A federal solution is anticipated soon, until then we appreciate your consideration of this necessary amendment for all Tennessee veterinarians and the animals under their care.

TDMHSAS Response:

The Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) thanks the Tennessee Veterinary Medical Associations (TVMA) for their comments and their ongoing commitment to addressing the evolving opioid crisis and acknowledging that Xylazine is now playing a major role in complicating the public health response to the crisis. While recent comments from the DEA suggest that the Xylazine found in the illicit samples likely comes from both legitimate sources, such as the veterinary controlled substance supply, and the illicit market, it is currently unknown how much Xylazine found in illicit substances originated from legitimate markets. After careful consideration, TDMHSAS will remove Xylazine from the proposed rule and continue to work with public and private stakeholders to gather additional data, provide education, and monitor related changes at the federal level and will consider scheduling Xylazine in future rule promulgation.

JANET D. DONLIN, DVM, EXECUTIVE VICE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AMERICAN VETERINARY MEDICAL ASSOCIATION:

The American Veterinary Medical Association (AVMA) recognizes the threat of illicit xylazine as it poses grave health and safety risks to human users. However, if scheduling of xylazine happens in Tennessee without an exemption for veterinary users, it would drastically change the way veterinarians are able to care for their patients, creating animal welfare and human safety concerns. As you can imagine, this is a huge concern for veterinarians and livestock producers.

Xylazine is a non-narcotic veterinary sedative, analgesic, and muscle relaxant that has been approved in the United States for veterinary use since 1972. It is used across veterinary medicine and is especially important when working with cattle, horses, zoo, wildlife, and laboratory species to facilitate safe medical evaluations, treatment, and surgical care.

Sedation of fractious and large animals with xylazine is critical to keeping people and animals safe. This drug is needed for safe cattle handling and when performing procedures such as disbudding/dehorning, treating leg or hoof injuries, and handling obstetrical complications such as pulling calves, performing Caesarian sections, and correcting uterine torsions. Xylazine can also be used to immobilize injured animals at processing plants before euthanizing and disposal in compliance with USDA humane handling requirements. There is <u>no</u> practical alternative for sedation in cattle. Limiting veterinary access to this critical drug will jeopardize animal welfare and human safety.

There are currently only two manufacturers of xylazine for veterinary use in the United States. Xylazine is a low-volume generic drug that generates little revenue for manufacturers and we do not believe there is a significant diversion from the legitimate veterinary distribution channel. Increased regulations on legitimate xylazine to address illicit xylazine will result in supply chain disruptions or eliminate the product from the market. If xylazine is scheduled as a controlled substance without an exemption for veterinary use, there is a very real risk that it will cease to be available in Tennessee because of the increased regulatory burden and costs for the manufacturers and distributors. It is our understanding that one of the manufacturers has already ceased making the product until there is more regulatory clarity and uniformity between states. This leaves one manufacturer currently providing product to the entire U.S. market.

The veterinary community is not taking the drug epidemic and the role xylazine plays lightly. Discussions with the U.S. Drug Enforcement Administration (DEA) and lawmakers led to federal legislation that would address this issue with enforcement tools to target illicit xylazine traffickers. The Combating Illicit Xylazine Act (H.R. 1839/S. 993) was introduced on March 28, 2023. This bicameral, bipartisan bill is supported by a long list of stakeholders, including us and the Tennessee Veterinary Medical Association (TVMA). The legislation would engage and equip the DEA with tools to combat illicit xylazine trafficking while maintaining veterinarians' access and ability to legitimately use this critical animal sedative regulated by the Food and Drug Administration as a prescription animal drug. It includes a provision requiring manufacturers and distributors of legitimate xylazine to report sales to DEA through an existing tracking system (ARCOS) and would identify any unusual activity or change in ordering patterns. This feature would not normally be part of scheduling a drug like xylazine. Additionally, any diversion of xylazine from the veterinary supply chain for unlawful use in humans would be subject to harsher penalties under the Controlled Substances Act.

Key elements of the Combating Illicit Xylazine Act were recently incorporated into the Support for Patients and Communities Reauthorization Act (H.R. 4531 or SUPPORT Act) and passed out of the House Energy and Commerce Committee on July 19. Floor action in the House is pending. This bill would schedule xylazine as a schedule III drug and exempt the FDA-approved animal drug from scheduling. This is an approach that Congress has taken before with another animal drug, as has Tennessee (see T.C.A. §39-17-404).

In addition, AVMA and TVMA supported TN H.B. 1242/TN S.B. 1398 which was signed into law this past May. This new law criminalizes possessing manufacturing, delivering, or selling xylazine in Tennessee while exempting legitimate veterinary practice and possession by non-veterinarians with valid prescriptions from a licensed veterinarian. In keeping with this recently enacted law, we respectfully request that any rule related to scheduling of xylazine exempt use in legitimate veterinary practice.

Suggested language:

Xylazine as a Schedule III substance except when it is used in any of the following manners:

- 1. Dispensing or prescribing for, or administration to, a nonhuman species of a drug containing Xylazine that has been approved by the Secretary of Health and Human Services under section 512 of The Federal Food, Drug, and Cosmetic Act (21 U.S.C.A. § 360b).
- 2. Dispensing or prescribing for, or administration to, a nonhuman species that is permissible under section 512(a)(4) of The Federal Food, Drug, and Cosmetic Act (21 U.S.C.A. § 360b(a)(4)).
- 3. The manufacturing, distribution or use of Xylazine as an active pharmaceutical ingredient for manufacturing an animal drug approved under section 512 of The Federal Food, Drug, and Cosmetic Act (21 U.S.C.A. § 360b or issued an investigation use exemption under subsection (j) of § 512.)
- 4. The manufacturing, distribution or use of a Xylazine bulk chemical for pharmaceutical compounding by licensed pharmacist or veterinarians.
- Another use approved or permissible under The Federal Food, Drug, and Cosmetic Act.

The AVMA continues to work with Congress, the Administration and Federal agencies on solutions to address this pressing public health issue while maintaining veterinarians' access and use of this critical veterinary drug. A federal solution is anticipated soon, until then we appreciate your consideration of this necessary amendment for all Tennessee veterinarians and the animals under their care.

TDMHSAS Response:

The Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) thanks the American Veterinary Medical Associations (AVMA) for their comments and their ongoing commitment to addressing the evolving opioid crisis and acknowledging that Xylazine is now playing a major role in complicating the public health response to the crisis. After careful consideration, TDMHSAS will remove Xylazine from the proposed rule and continue to work with public and private stakeholders to gather additional data, provide education, and monitor related changes at the federal level and will consider scheduling Xylazine in future rule promulgation.

CHLOE LIGON, DIRECTOR OF POLICY AND ADVOCACY, TENNESSEE ASSOCIATION OF MENTAL HEALTH ORGANIZATIONS (TAMHO):

I am writing today on behalf of the Tennessee Association of Mental Health Organizations (TAMHO) to provide feedback on the new TDMHSAS Controlled Substances Rules filed on 6/30/23. TAMHO represents not-for-profit community mental health and substance use providers who serve children, adults, and families across the state. Our members have thoroughly reviewed the new, proposed rules, and our feedback follows.

Thank you for taking our suggestions into consideration.

TAMHO recommends that is Xylazine is scheduled, legislation changing the current statute around test strips needs to be introduced. Currently, it is illegal to do test strips on scheduled drugs. We wish to see legislation in which test strips are permitted in the case of Xylazine, similar to what was done with Fentanyl previously. Ideally, the wording would be changed so that legalized strips are not substance-specific, but rather have the ability to be used broadly across substances.

TDMHSAS Response:

The Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) greatly appreciates the Tennessee Association of Mental Health Organizations' (TAMHO) comments and recommendations regarding the department's proposal to schedule Xylazine as a

controlled substance under our departmental rules. Specifically, TAMHO questions whether scheduling Xylazine as a controlled substance in rules will make Xylazine test strips illegal drug paraphernalia under Tennessee law and, if so, recommends legislation to prevent those test strips from being considered drug paraphernalia. It is this department's understanding that testing equipment is only considered drug paraphernalia when used to test for a controlled substance, as defined in the Tennessee Code at Title 39, Chapter 17, Part 4 (see definition of "drug paraphernalia" at T.C.A. § 39-17-402(12)). Adding Xylazine as a scheduled controlled substance under our department rules does not automatically place it in the Tennessee Code's schedule of controlled substances. Thus, this change to the rules should not affect whether these test strips are considered drug paraphernalia. The department recommends that all persons and entities consult their own attorneys regarding any specific legal concerns they may have. That said, and after careful consideration, TDMHSAS will remove Xylazine from the proposed rule and continue to work with public and private stakeholders to gather additional data, provide education, and monitor related changes at the federal level and will consider scheduling Xylazine in future rule promulgation.

Regulatory Flexibility Addendum

Pursuant to T.C.A. §§ 4-5-401 through 4-5-404, prior to initiating the rule making process, all agencies shall conduct a review of whether a proposed rule or rule affects small business.

These rules will not affect small businesses. Although, some pharmacies qualify as small businesses, the changes to the controlled substances schedules promulgated by these rules should not change the daily operations of those pharmacies.

Impact on Local Governments

Pursuant to T.C.A. §§ 4-5-220 and 4-5-228, "On any rule and regulation proposed to be promulgated, the proposing agency shall state in a simple declarative sentence, without additional comments on the merits or the policy of the rule or regulation, whether the rule or regulation may have a projected financial impact on local governments. The statement shall describe the financial impact in terms of increase in expenditures or decrease in revenues."

TDMHSAS believes that these rules will not have a projected financial impact on local governments.

Additional Information Required by Joint Government Operations Committee

All agencies, upon filing a rule, must also submit the following pursuant to T.C.A. § 4-5-226(i)(1).

A brief summary of the rule and a description of all relevant changes in previous regulations effectuated by such rule;

The lists of controlled substances for all schedules were revised to ensure consistency with Part 1308 of Title 21 of the Code of Federal Regulations (C.F.R.).

0940-06-01-.01 names controlled substances within Schedule I including opiates, opium derivatives, hallucinogenic substances, depressants, and stimulants. Newly identified stimulants, hallucinogens, and opiates that were scheduled at the federal level have been added.

0940-06-01-.04 names controlled substances within Schedule IV including narcotic drugs, depressants, and stimulants. A newly scheduled stimulant at the federal level has been added. Fenfluramine has been removed from this rule as it has been descheduled at the federal level.

0940-06-01-.05 names controlled substances within Schedule V including including narcotic drugs, depressants, and stimulants. A newly scheduled depressant at the federal level has been added.

A citation to and brief description of any federal law or regulation or any state law or regulation mandating promulgation of such rule or establishing guidelines relevant thereto;

Identification of persons, organizations, corporations or governmental entities most directly affected by this rule, and whether those persons, organizations, corporations or governmental entities urge adoption or rejection of this rule;

This rule affects healthcare professionals and pharmacies; as well as the TN Boards of Nursing, Medical Examiners, and Pharmacy; the TennCare Inspector General and the TN Bureau of Investigation. The Department received a comment from the TN Bureau of Investigation in favor of adopting the rule.

Identification of any opinions of the attorney general and reporter or any judicial ruling that directly relates to the rule or the necessity to promulgate the rule;

There are no opinions of the Attorney General and Reporter that directly relate to these rules.

An estimate of the probable increase or decrease in state and local government revenues and expenditures, if any, resulting from the promulgation of this rule, and assumptions and reasoning upon which the estimate is based. An agency shall not state that the fiscal impact is minimal if the fiscal impact is more than two percent (2%) of the agency's annual budget or five hundred thousand dollars (\$500,000), whichever is less;

It is estimated that these rules will not have a fiscal impact on state and local government revenues and expenditures.

Identification of the appropriate agency representative or representatives, possessing substantial knowledge and understanding of the rule;

Dr. Wesley Geminn, Chief Pharmacist, TDMHSAS
Krysten Velloff, Director of Legislation and Rules, TDMHSAS

Identification of the appropriate agency representative or representatives who will explain the rule at scheduled meeting of the committees:

Dr. Wesley Geminn, Chief Pharmacist, TDMHSAS Krysten Velloff, Director of Legislation and Rules, TDMHSAS

Office address, telephone number, and email address of the agency representative or representatives who will explain the rule at a scheduled meeting of the committees; and

500 Deaderick Street, 5th Floor, Andrew Jackson Building, Nashville, TN 37243 (615) 881-5280 Krysten.Velloff@tn.gov

Any additional information relevant to the rule proposed for continuation that the committee requests;

N/A

MENTAL HEALTH & SUBSTANCE ABUSE SERVICES ALCOHOL AND DRUG ABUSE SERVICES

CHAPTER 0940-06-01 CONTROLLED SUBSTANCES

TABLE OF CONTENTS

(e)

IADLE	OF CO	MIENIS					
0940-0	6-0101	Controlled Substances in Schedule I					
0940-06-0102 Controlled Substances in Schedule II							
0940-0	0940-06-0103 Controlled Substances in Schedule III						
0940-0	6-0104	Controlled Substances in Schedule IV					
0940-0	6-0105	Controlled Substances in Schedule V					
0940-0	6-0106	Controlled Substances in Schedule VI					
0940-0	6-0107	Controlled Substances in Schedule VII					
0940-0	6-0108	Non-Narcotic Substances Excluded from Controlled Substances					
0940-0	6-0109	Chemical Preparations Excluded from Controlled Substances					
0940-0	6-0110	Veterinary Anabolic Steroid Implant Products Excluded from Controlled Substances	5				
0940-0	6-0111	Prescription Products Excluded from Controlled Substances					
0940-0	6-0112	Anabolic Steroid Products Excluded from Controlled Substances					
0940-0	6-0113	Certain Cannabis Plant Material, and Products Made Therefrom, Excluded from Co	ntrolled Substances				
0940-0	6-0101	CONTROLLED SUBSTANCES IN SCHEDULE I.					
(1)	chemic	lle I consists of the drugs and other substances, by whatever official name, common al name, or brand name designated, listed in this rule. Each drug or substance bear nce code number assigned to it by the Drug Enforcement Administration.					
(2)	their iso	s. Unless specifically excepted or unless listed in another schedule, any of the follow omers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the es, esters, ethers, salts is possible within the specific chemical designation. For the pragraph (hhttps://hhttp	xistence of such urposes of				
	(a)	Acetylmethadol	. 9601				
	(b)	AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)	. 9551				
	(c)	Allylprodine	. 9602				
	(d)	Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol; levomethadyl acetate; or LAAM)	. 9603				

Alphameprodine......9604

(f)	Alphamethadol	9605
(g)	Benzethidine	9606
(h)	Betacetylmethadol	9607
(i)	Betameprodine	9608
(j)	Betamethadol	9609
(k)	Betaprodine.	. 9611
(I)	Brorphine	. 9098
<u>(m)</u>	Butonitazene	<u>9751</u>
<u>(n)(m)</u>	Clonitazene	. 9612
<u>(o)(n)</u>	Dextromoramide	. 9613
<u>(p)(o)</u>	Diampromide	. 9615
(<u>q)(p)</u>	Diethylthiambutene	. 9616
<u>(r)(q)</u>	Difenoxin	. 9168
<u>(s)(r)</u>	Dimenoxadol	9617
<u>(t)(s)</u>	Dimepheptanol	9618
<u>(u)(t)</u>	Dimethylthiambutene	. 9619
<u>(v)(u)</u>	Dioxaphetyl butyrate	. 9621
<u>(w)(v)</u>	Dipipanone	. 9622
<u>(x)(w)</u>	Ethylmethylthiambutene	. 9623
<u>(y)</u>	<u>Etodesnitazene</u> .	<u>. 9765</u>
<u>(z)(x)</u>	Etonitazene	. 9624
<u>(aa)(y)</u>	Etoxeridine	. 9625
<u>(bb)</u>	<u>Flunitazene</u>	<u>. 9756</u>
(cc) (z)	Furethidine	. 9626
(<u>dd</u> aa)	Hydroxypethidine	. 9627
(<u>ee</u> bb)	Isotonitazene	9614
(ffee)	Ketobemidone	. 9628

(gg dd)	Levomoramide	9629
(<u>hh</u> ee)	Levophenacylmorphan	9631
<u>(ii)</u>	Metodesnitazene.	<u>9764</u>
(ii)	Metonitazene. 9	<u>9757</u>
(<u>kk</u> ff)	Morpheridine	9632
(llgg)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
(mmhh)	MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)	9560
<u>(nn)</u>	N-pyrrolidino etonitazene.	<u>9758</u>
(<u>00</u> ii)	Noracymethadol	9633
(ppjj)	Norlevorphanol	9634
(<u>qq</u> kk)	Normethadone	9635
(<u>rr</u> #)	Norpipanone	9636
(<u>ss</u> mm)	PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine)	9663
(<u>tt</u> nn)	Phenadoxone	9637
(<u>uu</u> ee)	Phenampromide	9638
(<u>vv</u> pp)	Phenomorphan9	9647
(<u>ww</u> qq)	Phenoperidine	9641
(<u>xx) rr)</u>	Piritramide	9642
(<u>yy</u> ee)	Proheptazine	9643
(<u>zz</u> #)	Properidine	9644
<u>(aaa)</u>	Propiram9	<u>)649</u>
(<u>bbb</u> uu)	Protonitazene	<u>9759</u>
(<u>ccc</u> vv)	Racemoramide	9645
(<u>ddd</u> ww)) Tilidine	9750
(<u>eee</u> xx)	Trimeperidine9	9646
(<u>fff</u> yy)	U-47700	9547
(aaa)	Zipeprol.	9873

(hhhzz)Fentanyl Derivatives and Analogues.

- 1. Unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a 4-anilidopiperidine structure:
 - (i) With or without substitution at the carbonyl of the aniline moiety with alkyl, alkenyl, carboalkoxy, cycloalkyl, methoxyalkyl, cyanoalkyl, or aryl groups, or furanyl, dihydrofuranyl, benzyl moiety, or rings containing heteroatoms sulfur, oxygen, or nitrogen;
 - (ii) With or without substitution at the piperidine amino moiety with a phenethyl, benzyl, alkylaryl (including heteroaromatics), alkyltetrazolyl ring, or an alkyl or carbomethoxy group, whether or not further substituted in the ring or group;
 - (iii) With or without substitution or addition to the piperdine ring to any extent with one or more methyl, carbomethoxy, methoxy, methoxymethyl, aryl, allyl, or ester groups;
 - (iv) With or without substitution of one or more hydrogen atoms for halogens, or methyl, alkyl, or methoxy groups, in the aromatic ring of the anilide moiety;
 - (v) With or without substitution at the alpha or beta position of the piperidine ring with alkyl, hydroxyl, or methoxy groups;
 - (vi) With or without substitution of the benzene ring of the anilide moiety for an aromatic heterocycle; and
 - (vii) With or without substitution of the piperidine ring for a pyrrolidine ring, perhydroazepine ring, or azepine ring;
- 2. Excluding, Alfentanil, Carfentanil, Fentanyl, and Sufentanil; including, but not limited to:
 - (i) Acetylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)..... 9821

 - (vi) Benzodioxolefentanyl

(viii)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-4-yl]-N-phenylpropionamide; N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide)
(ix)	Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)
(x)	Beta-Methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide
(xi)	Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide)
(xii)	Butyrylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide)
(xiii)	Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N- phenylbut-2-enamide)
(xiv)	Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide)
(xv)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide)
(xvi)	Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate)
(xvii)	2'-Fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-n-(2-fluorophenyl)propionamide)
(xviii)	Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)
(xix)	Isobutyryl fentanyl (N-(1-phenethylpiperidin-4yl)-N-phenylisobutyramide)
(xx)	Lofentanil
(xxi)	Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)
(xxii)	4'-Methyl acetyl fentanyl (N-(1-(4- methylphenethyl)piperidin-4-yl)-N-phenylacetamide
(xxiii)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)
(xxiv)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
(xxv)	Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide)
(xxvi)	Ohmefentanyl

(xxvii)	Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide)
(xxviii)	Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)butyramide)
(xxix)	Ortho-fluorofentanyl (2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide)
(xxx)	Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin -4- yl)isobutyramide)
(xxxi)	Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1- phenethylpiperidin-4-yl)acetamide)
(xxxii)	Ortho-Methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide
(xxxiii)	Para-chloroisobutyryl fentanyl (N-(4-chloropenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)
(xxxiv)	Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
(xxxv)	Para-fluorofentanyl. (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide)
(xxxvi)	Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2-carboxamide)
(xxxvii)	Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide; 4-fluoroisobutyryl fentanyl
(xxxviii)	Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
(xxxix)	Para-methylfentanyl (N-(4-methylphenyl)-N-(1- phenethylpiperidin-4-yl)propionamide)
(xl)	Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide)9841
(xli)	Pentanoyl fentanyl
(xlii)	Tetrahydrofuranyl fentanyl (N-(1- phenethylpiperidin-4-yl)- nphenyltetrahydrofuran-2-carboxamide)
(xliii)	Thiofentanyl
(xliv)	Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylthiophene-2-carboxamide
(xlv)	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)

Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(a)	Acetorphine
(b)	Acetyldihydrocodeine
(c)	Benzylmorphine
(d)	Codeine methylbromide
(e)	Codeine-N-Oxide
(f)	Cyprenorphine
(g)	Desomorphine
(h)	Dihydromorphine
(i)	Drotebanol
(j)	Etorphine (except hydrochloride salt)
(k)	Heroin
(I)	Hydromorphinol9301
(m)	Methyldesorphine
(n)	Methyldihydromorphine
(o)	Morphine methylbromide
(p)	Morphine methylsulfonate
(p)	Morphine-N-Oxide
(r)	Myrophine
(s)	Nicocodeine
(t)	Nicomorphine
(u)	Normorphine
(v)	Pholcodine
(w)	Thebacon

⁽⁴⁾ Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and

salts of isomers, is possible within the specified chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

(a)	Alpha-ethyltryptamine Other names: etryptamine; Monase; [alpha]-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; [alpha]-ET; and AET; ET; Trip	7249
(b)	Alpha-methyltryptamine Other name: AMT	7432
(c)	Alpha-pyrrolidinobutiophenone Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one	7546
(d)	Alpha-pyrrolidinopentiophenoneOther names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one	
(e)	4-Bromo-2,5-dimethoxyamphetamineOther names: 4-Bromo-2,5-dimethoxy-[alpha]-methylphenethylamine; 4-bromo-2,5-DN	
(f)	4-Bromo-2,5-dimethoxyphenethylamineOther names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DO 2C-B; Nexus	
(g)	2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	7536
(h)	BufotenineOther names: 3-([beta]-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethylindolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine	
(i)	Butylone Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one	7541
(j)	2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	7537
(k)	Diethyltryptamine	7434
(I)	2,5-DimethoxyamphetamineOther names: 2,5-Dimethoxy-[alpha]-methylphenethylamine; 2,5-DMA	7396
(m)	2,5-Dimethoxy-4-ethylamphetamine.	7399
(n)	2,5 2,5 Dimethoxy-4propylthiophenethylamine	7348
(o)	Dimethyltryptamine	'435
(p)	Ethylamine analogue of phencyclidine	

<u>(q)</u>	2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one	.7286
<u>(r)(q)</u>	Ethylone	
	Other names: 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one; 3,4-methylenedi N-ethylcathinone; bk-MDEA; MDEC	oxy-
<u>(s)(r)</u>	Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate Other name: 5F-EDMB-PINACA	7036
<u>(t)(s)</u>	(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone	.7014
<u>(u)(t)</u>	3-Fluoro-N-methylcathinone	1233
<u>(v)(u)</u>	4-Fluoro-N-methylcathinone Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one	1238
<u>(w)(v)</u>	1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide	7083
<u>(x)(w)</u>	Ibogaine Other names: 7-Ethyl-6,6[beta],7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5hpyrido [1',2':1,2]azepino[5,4-b]indole; Tabenanthe iboga.	
<u>(y)(x)</u>	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	7538
<u>(z)(y)</u>	Lysergic acid diethylamide Other name: LSD	7315
<u>(aa)(z)</u>	Mescaline Other name: Constituent of "Peyote" cacti	7381
(<u>bb</u> aa)	4-Methoxyamphetamine Other names: 4-methoxy-[alpha]-methylphenethylamine; paramethoxyamphetamine;	
(ccbb)	5-Methoxy-3,4-methylenedioxyamphetamine	7401
(<u>dd</u> ee)	5-Methoxy-N,N-diisopropyltryptamineOther name: 5-MeO-DIPT	7439
(<u>ee</u> dd)	5-methoxy-N,N-dimethyltryptamine	7431
(<u>ff</u> ee)	4-Methyl-N-ethylcathinoneOther names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one	.1249
(<u>gg</u> ff)	4-Methyl-alpha-pyrrolidinopropiophenone	7498
(<u>hhgg</u>)	Methyl 2-(1-(cyclohexylmethyl)-1h-indole-3-carboxamido)-3,3-dimethylbutanoate Other names: MDMB-CHMICA, MMB-CHMINACA	7042

(<u>ii</u> hh)	4-Methyl-2,5-dimethoxyamphetamine	. 7395
(<u>jj</u> ii)	3,4-Methylenedioxyamphetamine	7400
(<u>kk</u> jj)	3,4-Methylenedioxymethamphetamine	7405
(<u> </u> kk)	3,4-Methylenedioxy-N-ethylamphetamine	
(<u>mm</u> #)	3,4-Methylenedioxy-N-methylcathinone	7540
<u>(nn)</u>	Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate Other names: MDMB-FUBINACA	.7020
(<u>oo</u> mm)	Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate Other name: 4F-MDMB-BINACA Methyl 2_(1-(4-fluorobenzyl)-1h-indazole-3-carboxamido)-3,3-dimethylbutanoate 7020 Other name: MDMB-FUBINACA	<u>.7043</u>
(nn)	Methyl2-(1-(5-fluoropentyl)-1h-indazole-3-carboxamido)-3,3-dimethylbutanoate	.7034
	Other names: 5F-ADB, 5F-MDMB-PINACA	7 U34
(ppee)	Methyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate Other names: 5F-ADB; 5F-MDMB-PINACA	.7034
<u>(qq)</u>	_Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate Other name: 5F-AMB	7033
(<u>rrpp</u>)	Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate Other name: 5F-MDMB-PICA	7041
(<u>ss</u> qq)	N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide	7047
(<u>tt</u> ff)	N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide Other names: 5F-APINACA, 5F-AKB48	. 7049
(<u>uu</u> ss)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)1H-indazole-3-carboxamideOther name: ADB-FUBINACA	7010
(<u>vv</u> tt)	NaphyroneOther names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-	.1258 one
(<u>ww</u> uu)	Naphthalen-1-yl 1-(5-fluoropentyl)-1 h-indole-3-carboxylate Other names: NM2201; CBL2201	. 7221
(<u>xx</u> ++)	N-Ethyl-3-piperidyl benzilate.	7482

(<u>yy</u> ww)	N-Hydroxy-3,4-methylenedioxyamphetamine Other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine; N-hydro MDA	
(<u>zz</u> xx)	N-methyl-3-piperidyl benzilate	7484
(<u>aaayy)</u>	ParahexylOther names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b, d]pyran; Synhexyl	7374
(<u>bbbzz)</u>	Para-methoxymethamphetamine Other names: PMMA, 1-(4- methoxyphenyl)-n-methylpropan-2-amine	1245
(<u>ccc</u> aaa	a)Pentedrone,	
	Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-	1-one
(<mark>ddd</mark> bbl	Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one	7542
(<u>eee</u> cce	Meaning all parts of the plant presently classified botanically as Lophophora williamsi Lamaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of plant its seeds or extracts. (Interprets 21 USC 812(c), Schedule 1 (c)(12)(o))	i 1
(<u>fff</u> ddd)	Psilocybin (constituent of magic mushrooms)	7437
(ggg ee	e)Psilocyn (constituent of magic mushrooms)	7438
(<u>hhh</u> fff)	Pyrrolidine analogue of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine) Other names: PCPy; PHP	7458
(<u>iiiggg</u>)	1-[1-(2-Thienyl)cyclohexyl]pyrrolidineOther name: TCPy	7473
(<mark>jjjhhh</mark>)	4-Methylmethcathinone Other names: mephedrone; methpadrone; 4-MMC	1248
(<u>kkk</u> iii)	3,4-Methylenedioxypyrovalerone	7535
(<u> </u> jjj)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)	7509
(<u>mmm</u> k	kk)2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)	7508
(<u>nnn</u> #)2	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)	7519
(<u>000</u> mn	nm)2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-l)	7518
(<u>ppp</u> nnı	P)2-[4-Ethylthio-2,5-dimethoxyphenyl]ethanamine (2C-T-2)	7385
00 000)	e)2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)	7532
(rrr ppp)	2-(2.5-Dimethoxyphenyl)ethanamine (2C-H)	7517

(<u>sss</u> qq	q)2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)	7521
(<u>ttt</u> rrr)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)	7524
(<u>uuu</u> ss	Control of the contro	7470
(<u>vvv</u> ttt)	3,4,5-Trimethoxyamphetamine	7390
(<u>www</u> u	Other names: UR-144; 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)methanone	7144
(<u>xxx</u> vv	v)1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	7011
(<u>ууу</u> ₩₩	ww)(1-(5-Fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone	7024
(<u>zzz</u> xx)	x)5F-CUMYL-P7AICAOther names: 1-(5-fluoropentyl)-n-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide	
(<u>aaaa</u> y	yyy)MMB-CHMICAOther names: methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate; AMB-CHMICA	7044
(<u>bbbb</u> z	Other names: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide; cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SGT-78	
(<u>cccc</u> a	aaa)5F-AB-PINACAOther names: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3 carboxamide	
(<u>dddd</u> b	obbb)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3- carboxamide Other name: AB-CHMINACA	7031
(<u>eeee</u> e	carboxamideOther name: AB-FUBINACA	7012
(ffffddd	ld)N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide Other names: APINACA; AKB48	7048
(<u>gggg</u> e	carboxamideOther name: ADB-PINACA	7035
(<u>hhhh</u> f	fff)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide Other name: AB-PINACA	.7023

	(<u>iiiigggg</u>	Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	7225
	(jjjjhhhh	A)Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate Other names: PB-22; QUPIC	7222
	(<u>kkkk</u> iiii)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carbo its optical, positional, and geometric isomers, salts and salts of isomers Other names: MAB-CHMINACA; ADB-CHMINACA	
	(<u> jjjj</u>)	Methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3-methylbutanoate Other names: FUB-AMB, MMB-FUBINACA, AMB-FUBINACA	7021
(5)	prepara nervous	sants. Unless specifically excepted or unless listed in another schedule, any material, ation which contains any quantity of the following substances having a depressant effects system, including its salts, isomers, and salts of isomers whenever the existence of sisomers is possible within the specified chemical designation:	ect on the central
	(a)	Etizolam Other names; Etilaam, Etizola, Sedekopan, Pasaden, Depas	2780
	(b)	Gamma-hydroxybutyric acid	
	(c)	Mecloqualone	. 2572
	(d)	Methaqualone	. 2565
(6)	prepara	ants. Unless specifically excepted or unless listed in another schedule, any material, co ation which contains any quantity of the following substances having a stimulant effect , including its salts, isomers, and salts of isomers:	
	<u>(a)</u>	Amineptine. Other names: 7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic ad	1219 cid
	<u>(b)(a)</u>	Alpha-Pyrrolidinoheptaphenone Other names: PV8, 1-phenyl-2-(pyrrolidin-1- yl)heptan-1-one	7548
	<u>(c)(b)</u>	Alpha-Pyrrolidinohexanophenone	7544 xan-1-
	<u>(d)(c)</u>	Aminorex Other names: aminoxophen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-oxazolamine	
	<u>(e)(d)</u>	Cathinone Other names: 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone; 2-aminopropiophenone; norphedrone; constituent of catha edulis or "Khat" plant	1235
	<u>(f)(e)</u>	4'-Chloro-alpha-pyrrolidinovalerophenone	

<u>(g)(f)</u>	4,4'-Dimethylaminorex Other names: 4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine	1595
<u>(h)(g)</u>	EphyloneOther names: N-ethylpentylone; 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-o	7543 one
<u>(i)(h)</u>	Fenethylline	. 1503
<u>(i)</u>	Mesocarb. Other names: N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl) carbamimidate	1227
<u>(k)(i)</u>	Methcathinone	e; 2-
<u>(I)</u>	Methiopropamine.	1478
	Other names: N-methyl-1-(thiophen-2-yl)propan-2- amine	
<u>(m)(j)</u>	4-Methyl-alpha-ethylaminopentiophenoneOther names: 4-MEAP, 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one	7245
<u>(n)(k)</u>	4'-Methyl-alpha-pyrrolidinohexiophenoneOther names: MPHP, 4'-methyl-alpha-pyrrolidinohexanophenone, 1-(4-methylpheny (pyrrolidin-1-yl)hexan-1-one	
<u>(o)(l)</u>	(+/-) cis-4-Methylaminorex (cis isomer)	1590
<u>(p)(m)</u>	N-BenzylpiperazineOther names: BZP; 1-benzylpiperazine	7493
<u>(q)(n)</u>	N-Ethylamphetamine	1475
<u>(r)(o)</u>	N-EthylhexedroneOther name: 2-(ethylamino)-1-phenylhexan-1-one	7246
<u>(s)(p)</u>	N,N-DimethylamphetamineOther names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenetl	
mixture isomer	bimimetic agents. Unless specifically exempted or unless listed in another schedule, e, or preparation which contains any quantity of the following substances, or which cos, and salts of isomers whenever the existence of such salts, isomers, and salts of isocific chemical designation:	ontains their salts,
(a)	5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)	7297
(b)	5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexano 47,497 C8-homolog)	
(c)	1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)	7118
(d)	1-Butyl-3-(1-naphthoyl)indole (JWH-073)	7173

(7)

(e)	1-Hexyl-3-(1-naphthoyl)indole (JWH-019)	7019
(f)	1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)	7200
(g)	1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)	6250
(h)	1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)	7081
(i)	1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)	7122
(j)	1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)	7398
(k)	1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	7201
(I)	1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	7694
(m)	1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4)	7104
(n)	1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)	7008
(o)	1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)	7203

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403, and 39-17-406.

0940-06-01-.02 CONTROLLED SUBSTANCES IN SCHEDULE II.

- (1) Schedule II consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
 - (a) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, thebaine-derived butorphanol, naldemedine, nalmefene, nalbuphine, naloxegol, naloxone, 6β-naltrexol and naltrexone, and their respective salts, but including the following:

1.	Codeine	9050
2.	Dihydroetorphine	9334
3.	Ethylmorphine	9190
4.	Etorphine hydrochloride	9059
5.	Granulated opium	9640
6.	Hydrocodone	9193
7.	Hydromorphone	9150

		9.	Morphine	9300
		10.	Noroxymorphone	9668
		11.	Opium extracts	9610
		12.	Opium fluid	. 9620
		13.	Oripavine	9330
		14.	Oxycodone	. 9143
		15.	Oxymorphone	9652
		16.	Powdered opium	9639
		17.	Raw opium	9600
		18.	Thebaine	9333
		19.	Tincture of opium	9630
	(b)	identica	It, compound, derivative, or preparation thereof which is chemically equivalen al with any of the substances referred to in paragraph (2)(a) of this rule, excepubstances shall not include the isoquinoline alkaloids of opium.	
	(c)	Opium	poppy and poppy straw	
	(d)	(includi of isom which is substar	eaves (9040) and any salt, compound, derivative or preparation of coca leave ng cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives a ers and derivatives), and any salt, compound, derivative, or preparation there is chemically equivalent or identical with any of these substances, except that not include decocainized coca leaves or extraction of coca leaves, ons do not contain cocaine or ecgonine.	and salts eof the
	(e)		ntrate of poppy straw (the crude extract of poppy straw in either liquid, solid on nich contains the phenanthrene alkaloids of the opium poppy)	
(3)	includin existen	g its iso	s specifically excepted or unless in another schedule any of the following opia mers, esters, ethers, salts and salts of isomers, esters and ethers whenever t ch isomers, esters, ethers, and salts is possible within the specific chemical d d levopropoxyphene excepted:	the
	(a)	Alfenta	nil	9737
	(b)	Alphap	rodine	9010
	(c)	Anilerid	line	9020
	(d)	Bezitra	mide	9800
	(e)	Carfent	anil	9743

8.

(f)	Dextropropoxyphene (bulk, non dosage forms)	9273
(g)	Dihydrocodeine	9120
(h)	Diphenoxylate	9170
(i)	Fentanyl	9801
(j)	Isomethadone	9226
(k)	Levo-alphacetylmethadolOther names: levo-alpha-acetylmethadol; levomethadyl acetate; LAAM	9648
(I)	Levomethorphan	9210
(m)	Levorphanol	9220
(n)	Metazocine	9240
(o)	Methadone	9250
(p)	Methadone-Intermediate; 4-cyano-2-dimethylamino-4,4-diphenyl butane	9254
(q)	Moramide-Intermediate; 2-methyl-3-morpholino-1,1-diphenylpropane-caboxylic acid	. 9802
(r)	Oliceridine	9245
(s)	Pethidine (meperidine)	. 9230
(t)	Pethidine-Intermediate-A; 4-cyano-1-methyl-4-phenylpiperidine	9232
(u)	Pethidine-Intermediate-B; ethyl-4-phenylpiperidine-4-carboxylate	9233
(v)	Pethidine-Intermediate-C; 1-methyl-4-phenylpiperidine-4-carboxylic acid	9234
(w)	Phenazocine	. 9715
(x)	Piminodine	. 9730
(y)	Racemethorphan	. 9732
(z)	Racemorphan	. 9733
(aa)	Remifentanil	. 9739
(bb)	Sufentanil	9740
(cc)	Tapentadol	. 9780
(dd)	Thiafentanil	. 9729

(4)		ants. Unless specifically excepted or unless listed in another schedule, any material, ation which contains any quantity of the following substances having a stimulant effect.	
	(a)	Amphetamine, its salts, optical isomers, and salts of its optical isomers	1100
	(b)	Methamphetamine, its salts, isomers, and salts of its isomers	1105
	(c)	Phenmetrazine and its salts	. 1631
	(d)	Methylphenidate	. 1724
	(e)	Lisdexamfetamine, its salts, isomers, and salts of its isomers	1205
(5)	prepara nervous	sants. Unless specifically excepted or unless listed in another schedule any material ation which contains any quantity of the following substances having a depressant essistem, including its salts, isomers, and salts of isomers whenever the existence of isomers is possible within the specific chemical designation:	ffect on the central
	(a)	Amobarbital	. 2125
	(b)	Glutethimide	2550
	(c)	Pentobarbital	2270
	(d)	Phencyclidine	. 7471
	(e)	Secobarbital	2315
(6)	Hallucii	nogenic substances.	
	(a)	NabiloneOther names: (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydrodimethyl-9H-dibenzo[b,d]pyran-9-one	
	(b)	Dronabinol in oral solution in drug product approved for marketing by United States Drug Administration Other name: Syndros	
(7)		iate precursors. Unless specifically excepted or unless listed in another schedule, at or preparation which contains any quantity of the following substances:	ny material, compound,
	(a)	Immediate precursor to amphetamine and methamphetamine:	
		Phenylacetone Other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl bel	
	(b)	Immediate precursors to phencyclidine (PCP):	
		1. 1-phenylcyclohexylamine	. 7460
		1-piperidinocyclohexanecarbonitrile (PCC)	. 8603
	(c)	Immediate precursor to fentanyl:	

1. 2. Tianeptine and any salt, sulfate, free acid, or other preparation of tianeptine, and any salt, sulfate, free acid. (8)compound, derivative, precursor, or other preparation thereof that is substantially chemically equivalent or identical with tianeptine. Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403, and 39-17-408. 0940-06-01-.03 CONTROLLED SUBSTANCES IN SCHEDULE III. Schedule III consists of the drugs and other substances by whatever official name, common or usual name, (1) chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration. (2) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (a) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under 21 C.F.R. 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it Benzphetamine 1228 (b) (c) (d) Phendimetrazine 1615 (e) (3)Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect in the central nervous system: Any compound, mixture, or preparation containing: (a) Amobarbital 2126 1. 2. Secobarbital 2316 3. Or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

Any suppository dosage form containing:

(b)

1.

	2.	Secobarbital	2316
	3.	PentobarbitalOr any salt of these drugs and approved by the Food and Drug Administration marketing only as a suppository.	
(c)		ubstance which contains any quantity of a derivative of barbituric acid or any sauples include the following drugs:	
	1.	Aprobarbital	2100
	2.	Butabarbital (secbutabarbital)	2100
	3.	Butalbital	2100
	4.	Butobarbital (butethal)	2100
	5.	Talbutal	2100
	6.	Thiamylal	2100
	7.	Thiopental	2100
	8.	Vinbarbital	2100
(d)	Chlorh	hexadol	2510
(e)	Embu	ıtramide	2020
(f)	acid, i	ma hydroxybutyric acid preparations. Any drug product containing gamma hydro including its salts, isomers, and salts of isomers, for which an application is approof the federal Food, Drug, and Cosmetic Act, codified in 21 U.S.C. §§ 301, et so	oved under
(g)		nine, its salts, isomers, and salts of isomers name: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone	7285
(h)	Lyser	gic acid	7300
(i)	Lyser	gic acid amide	7310
(j)	Methy	/prylon	2575
(k)	Peram	npanel, and its salts, isomers, and salts of isomers	2261
(I)	Sulfon	ndiethylmethane	2600
(m)	Sulfon	nethylmethane	2605
(n)	Sulfon	nmethane	2610
(o)	Tiletar	mine and zolazepam or any salt of tiletamine or zolazepam	7295
	1.	Other name for a tiletamine-zolazepam combination product: Telazol®.	

		2.	Other name for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.	
		3.	Other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazee],[1,4]-diazepin-7(1H)-one; flupyrazapon.	olo[3,4-
(4)	Nalor	phine		9400
(5)	Narco	otic Drug	S.	
	(a)	prepa	es specifically excepted or unless listed in another schedule, any material, compound ration containing any of the following narcotic drugs, or their salts calculated as the or alkaloid, in limited quantities as set forth below:	
		1.	Not more than 8 grams of codeine per 100 milliliters or not more than 90 milligral dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opiun	n .
		2.	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 millign per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts	
		3.	Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 9 milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amounts	
		4.	Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more that milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amounts	
		5.	Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or no than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredi recognized therapeutic amounts	ents in
		6.	Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, wit or more active, non-narcotic ingredients in recognized therapeutic amounts	
	(b)	Any n	naterial, compound, mixture, or preparation containing any of the following narcotic	drugs or their salts:
		1.	Buprenorphine	. 9064
(6)			oids. Unless specifically excepted or unless listed in another schedule, any material eparation containing any quantity of the following substances, including its salts, es	
	(a)	Anab	olic steroids	. 4000
		1.	3[alpha],17[beta]-dihydroxy-5a-androstane	
		2.	17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane	
		3.	17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5a-androstane	
		4.	17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene	
		5.	17[alpha]-methyl-[delta]1-dihydrotestosterone(17[beta]-hydroxy-17[alpha]-methy 5[alpha]-androst-1-en-3-one) Other name: 17-[alpha]-methyl-1-testosterone	 -

- 6. 17[alpha]-methyl-4-hydroxynandrolone(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one)
- 7. 1-Androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
- 8. 1-Androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
- 9. 4-Androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene)
- 10. 5-Androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene)
- 11. 1-Androstenedione (5[alpha]-androst-1-en-3,17-dione)
- 12. 4-Androstenedione (androst-4-en-3,17-dione)
- 13. 5-Androstenedione (androst-5-en-3,17-dione)
- 14. 3[Beta],17[Beta]-dihydroxy-5a-androstane
- 15. 13[Beta]-ethyl-17[beta]-hydroxygon-4-en-3-one
- 16. Androstanedione (5[alpha]-androstan-3,17-dione)
- 17. Bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- 18. Boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one)
- 19. Boldione (androsta-1,4-diene-3,17-dione)
- 20. Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- 21. Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one) Other name: 4-Chlorotestosterone
- 22. Dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one)
- 23. [Delta]1-dihydrotestosterone (a.k.a.'1-testosterone') (17[Beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 24. Desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[Beta]-ol) Other name: madol
- 25. 4-Dihydrotestosterone (17[beta]-hydroxyandrostan-3-one)
- 26. Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one)
- 27. Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene)
- 28. Fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one)
- 29. Formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one)

- 30. Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)
- 31. 4-Hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one)
- 32. 4-Hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one)
- 33. Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 34. Mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 35. Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-diene-3-one)
- 36. Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene)
- 37. Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one)
- 38. Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 39. Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one)
- 40. Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one)
- 41. Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4, 9,11-trien-3-one)
- 42. Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one)
- 43. Nandrolone (17[beta]-hydroxyestr-4-en-3-one)
- 44. 19-Nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
- 45. 19-Nor-4-androstenediol (3[alpha],17[beta]-dihydroxyestr-4-ene)
- 46. 19-Nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene)
- 47. 19-Nor-5-androstenediol (3[alpha],17[beta]-dihydroxyestr-5-ene)
- 48. 19-Nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene)
- 49. 19-Nor-4-androstenedione (estr-4-en-3,17-dione)
- 50. 19-Nor-5-androstenedione (estr-5-en-3,17-dione)
- 51. Norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one)
- 52. Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one)
- 53. Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one)
- 54. Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one)
- 55. Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one)
- 56. Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one)

- 57. Oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-[5[alpha]]-androstan-3-one)
- 58. Prostanozol (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pryazole)
- 59. Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]-androst-2-eno[3,2-c]-pyrazole)
- 60. Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one)
- 61. Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1, 4-dien-17-oic acid lactone)
- 62. Testosterone (17[beta]-hydroxyandrost-4-en-3-one)
- 63. Tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4, 9,11-trien-3-one)
- 64. Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one)
- (b) Any salt, ester, or isomer of a drug or substance described or listed in subparagraph (a), if such salt, ester, or isomer promotes muscle growth.
- (c) Anabolic steroids intended for administration to cattle or other non-human species are exempt from this rule unless such steroids are prescribed, dispensed, or distributed for human use.
- (d) Anabolic steroids with a combination of estrogens intended for administration to hormone deficient women are exempt from this rule unless such steroids are prescribed, dispensed, or distributed to women who are not hormone deficient.

(7) Hallucinogenic Substances

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.04 CONTROLLED SUBSTANCES IN SCHEDULE IV.

- (1) Schedule IV consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

- (c) Tramadol, its salts, optical and geometric isomers, and salts of these isomers............ 9752 Other names: Ultram® and Ultracet®
- (3) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(a)	Alfaxalone	2731
(b)	Alprazolam	2882
(c)	Barbital	2145
(d)	Brexanolone	2400
(e)	Bromazepam	2748
(f)	Camazepam	2749
(g)	Carisoprodol	8192
(h)	Chloral betaine.	2460
(i)	Chloral hydrate	2465
(j)	Chlordiazepoxide	2744
(k)	Clobazam	2751
(I)	Clonazepam2	2737
(m)	Clorazepate	2768
(n)	Clotiazepam2	2752
(o)	Cloxazolam2	2753
<u>(p)</u>	Daridorexant 2	<u>410</u>
(q)(p)	Delorazepam	754
<u>(r)(q)</u>	Diazepam2	2765
<u>(s)(r)</u>	Dichloralphenazone. 2	2467
<u>(t)(s)</u>	Estazolam	756
<u>(u)(t)</u>	Eszopiclone	1/A
<u>(v)(u)</u>	Ethchlorvynol29	540
(w) (v)	Ethinamate	545

<u>(x)(w)</u>	Ethyl Loflazepate	2758
<u>(y)(x)</u>	Fludiazepam	2759
<u>(z)(y)</u>	Flunitrazepam	2763
<u>(aa)(z)</u>	-Flurazepam	2767
(<u>bb</u> aa)	Fospropofol	2138
(<u>cc</u> bb)	Halazepam	2762
(<u>dd</u> ee)	Haloxazolam	2771
(<u>ee</u> dd	-Ketazolam	2772
(<u>ff</u> ee)	Lemborexant	2245
(ggff)	Loprazolam	2773
(<u>hhgg</u>)	Lorazepam	2885
(<u>ii</u> hh)	Lormetazepam	2774
(<u>jj</u> ii)	Mebutamate	2800
(<u>kk</u> jj)	Medazepam	2836
(<u> </u> kk)	Meprobamate	2820
(<u>mm</u> H)	Methohexital	2264
(<u>nn</u> mm)	Methylphenobarbital (mephobarbital)	. 2250
(<u>oonn</u>)	Midazolam	2884
(ppee)	Nimetazepam	2837
(qq<u>pp</u>)	Nitrazepam	2834
(<u>rrqq</u>)	Nordiazepam	2838
(<u>ss</u> ff)	Oxazepam	2835
(<u>tt</u> ss)	Oxazolam	2839
(<u>uu</u> tt)	Paraldehyde	2585
(<u>vv</u> uu)	Petrichloral	2591
(<u>ww</u> vv)	Phenobarbital	2285
(<u>xx</u> ww)	Pinazepam	2883

	(<u>yy</u> xx)	Prazepam	2764
	(<u>zz</u> yy)	Quazepam	2881
	(<u>aaazz</u>) Remimazolam	2846
	(<u>bbb</u> aa	a)Suvorexant	2223
	(<u>ccc</u> bb	b)Temazepam	2925
	(<u>ddd</u> ee	<mark>e</mark>)Tetrazepam	2886
	(<u>eee</u> dd	l <mark>d</mark>)Triazolam	2887
	(<u>fff</u> eee)	Zaleplon	2781
	(gggfff)	Zolpidem	2783
	(<u>hhhg</u> g	g)Zopiclone	2784
(4)	substa	ramine. Any material, compound, mixture, or preparation which contains any quantity on new including its salts, isomers (whether optical, positional, or geometric), and salts of ver the existence of such salts, isomers, and salts of isomers is possible:	
	(a)	Fenfluramine	1670
	(b)	Dexfenfluramine	 1670
<u>(4)(5)</u>	substa	erin. Any material, compound, mixture, or preparation which contains any quantity of the nces, including its salts, isomers, and salts of such isomers, whenever the existence of s, and salts of isomers is possible:	
	(a)	Lorcaserin.	1625
<u>(5)(6)</u>	or prep	ants. Unless specifically excepted or unless listed in another schedule, any material, co paration which contains any quantity of the following substances having a stimulant efforts s system, including its salts, isomers and salts of isomers:	
	(a)	Cathine ((+)-norpseudoephedrine)	1230
	(b)	Diethylpropion	1610
	(c)	Fencamfamin	1760
	(d)	Fenproporex	1575
	(e)	Mazindol	1605
	(f)	Mefenorex	1580
	(g)	Modafinil	1680
	(h)	Pemoline (including organometallic complexes and chelates thereof)	1530

	(1)	Phentermine	1640
	(j)	Pipradol	1750
	(k)	Serdexmethylphenidate	1729
	(I)	Sibutramine	1675
	(m)	Solriamfetol	1650
	(n)	SPA ((-)-1-dimethylamino-1,2-diphenylethane)	1635
(7)		substances. Unless specifically excepted or unless listed in another schedule, any material, or preparation which contains any quantity of the following substances, including its salt	
	(a)	Pentazocine	9709
	(b)	Butorphanol (including its optical isomers)	9720
	(c)	Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1sphenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers	aĺ `

. . . .

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403, and 39-17-412.

0940-06-01-.05 CONTROLLED SUBSTANCES IN SCHEDULE V.

- (1) Schedule V consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
 - (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
 - (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
 - (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
 - (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
 - (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
 - (f) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
- (3) Stimulants. Unless specifically exempted or excluded, or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers:

	(a)	Pyrovalerone	. 1485
(4)	Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:		
	(a)	Brivaracetam ((2S)-2-[(4R)-2-oxo-4- propylpyrrolidin-1-yl] butanamide)	. 2710
	(b)	Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2- yl)ethyl]carbamate)	2720
	(c)	Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester]	2779
	(d)	Gabapentin [1-(aminomethyl)cyclohexaneacetic acid]	
	<u>(e)</u>	Ganaxolone (3-alpha-hydroxy-3-beta-methyl-5-alpha-pregnan-20-one)	<u> 2401</u>
	<u>(f)(e)</u>	Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide]	. 2746
	<u>(g)(f)</u>	Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)benzamide]	. 2790
	<u>(h)(g)</u>	Pregabalin [(S)-3-(aminomethyl)-5-methylhexonoic acid]	. 2782
Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.			
0940-06-0106 CONTROLLED SUBSTANCES IN SCHEDULE VI.			
(1)	Marijua	ana	7360
(2)	Tetrah	ydrocannabinols	. 7370
(3)	Unless specifically excepted or unless listed in another schedule, synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity. Examples include the following drugs or their compounds regardless of numerical designation of atomic positions covered:		
	(a)	1 cis or trans tetrahydrocannabinol, and its optical isomers.	
	(b)	6 cis or trans tetrahydrocannabinol, and its optical isomers.	

0940-06-01-.07 CONTROLLED SUBSTANCES IN SCHEDULE VII.

(1) Butyl nitrite and any isomer of butyl nitrite.

(c)

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

 $Authority: T.C.A. ~\S\S~4-4-103, ~33-1-302, ~33-1-303, ~33-1-305, ~33-1-309, ~and ~39-17-403.$

0940-06-01-.08 NON-NARCOTIC SUBSTANCES EXCLUDED FROM CONTROLLED SUBSTANCES.

3, 4 cis or trans tetrahydrocannabinol, and its optical isomers.

(1) Non-narcotic substances listed in the most current edition of 21 C.F.R. 1308.22, are excluded from all schedules. Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.09 CHEMICAL PREPARATIONS EXCLUDED FROM CONTROLLED SUBSTANCES.

(1) Chemical preparations listed in the most current edition of 21 C.F.R. 1308.24, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.10 VETERINARY ANABOLIC STEROID IMPLANT PRODUCTS EXCLUDED FROM CONTROLLED SUBSTANCES.

(1) Veterinary anabolic steroid implant products listed in the most current edition of 21 C.F.R. 1308.26, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.11 PRESCRIPTION PRODUCTS EXCLUDED FROM CONTROLLED SUBSTANCES.

(1) Prescription products listed in the most current edition of 21 C.F.R. 1308.32, are excluded from all schedules. Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.12 ANABOLIC STEROID PRODUCTS EXCLUDED FROM CONTROLLED SUBSTANCES.

(1) Anabolic steroid products listed in the most current edition of 21 C.F.R. 1308.34, are excluded from all schedules. Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-309, and 39-17-403.

0940-06-01-.13 CERTAIN CANNABIS PLANT MATERIAL, AND PRODUCTS MADE THEREFROM, EXCLUDED FROM CONTROLLED SUBSTANCES.

(1) Certain cannabis plant material, and products made therefrom, that contain tetrahydrocannabinols listed in the most current edition of 21 C.F.R. 1308.35, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.